Jim Cramer -- Corbus Pharma Shows the Upside of Biotech Risk

Shares of Corbus Pharmaceuticals (CRBP) are up a whopping 73% on Monday after the company's positive phase II results for its Resunab drug. 

The company can do many interesting things with this drug, said TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, on CNBC's "Stop Trading" segment. 

Cramer also reminded investors that he had the CEO of Corbus Pharma, Dr. Yuval Cohen, on his "Mad Money" show in October. At the time, he called the stock a speculative play, because of its small market cap and higher risk. 

However, that risk seems to have paid off this morning, with shares hovering near new highs. 

There were a lot of short-sellers in this stock. When it comes to biotech stocks like this, Cramer said, the results are very binary. The companies are either going to hit it big or go bust. 

Either buying or selling in that situation can be dangerous. But after the good phase II results, those jumping in on the short side are doing so without an edge, Cramer said, and that's never a good move. 

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

2 More Reasons to Sell All Your Stocks and Run Away

2 More Reasons to Sell All Your Stocks and Run Away

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast